Clinical Trials Logo
  1. Home
  2. Acinetobacter Infections
  3. NCT00524563
  4. Details
NCT00524563 Clinical Trial

Clinical Outcomes and Global Epidemiology -Data Coordinating Center

Acinetobacter Infections Clinical Trial

Official title:
Clinical Outcomes and Global Epidemiology -Data Coordinating Center

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00524563
Other study ID # PRO07080042
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 2007
Est. completion date June 2017

Study information
Verified date June 2018
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary objective is to assess for independent predictors of in-hospital mortality (up to 28 days) in patients with Acinetobacter bloodstream infection. Secondary Objectives include the following: To determine the impact of inactive empiric antimicrobial therapy, defined as receipt of empiric antimicrobial therapy with no in vitro activity against the offending isolate for at least 24hrs, on the outcome (end points defined below) of patients with Acinetobacter bloodstream infection. To determine the impact of carbapenem resistance and pan-drug resistance (defined as resistance to all antimicrobials except colistin and/or tigecycline if these agents were tested) on the outcome of patients with Acinetobacter bloodstream infection. To assess the efficacy of varying definitive therapies on the outcome of patients with Acinetobacter bloodstream infection. To characterize the molecular epidemiology of Acinetobacter on a global level, as determined by pulsed-field gel electrophoresis (PFGE) and other techniques, and to assess whether patient outcomes are clonally related and to characterize the mechanisms of resistance in Acinetobacter on a global scale.

Description:

Medical records will be reviewed and information collected from charts to assess for independent predictors of in-hospital mortality (up to 28 days) in patients with Acinetobacter bloodstream infection. 24 sites will participate and all information will be loaded into a password protected database.

Recruitment information / eligibility
Status Completed
Enrollment 400
Est. completion date June 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Acinetobacter bloodstream infection

Exclusion Criteria:

- Does not meet entry criteria

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
United States University of Pittsburgh Medical Center Pittsburgh Pennsylvania

Sponsors (1)
Lead Sponsor Collaborator
University of Pittsburgh

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT02688322 - Pharmacodynamics Modeling to Optimize Dosage Regimens of Sulbactam in Patients With Acinetobacter Infections Phase 4
Completed NCT03622918 - Colistin-rifampin Combination and Colistin Monotherapy in Extensively Drug-resistant Acinetobacter Baumannii N/A
Enrolling by invitation NCT05880069 - Clinical Outcomes in Patients With Infection by Resistant Microorganism
Completed NCT02482961 - Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection
Terminated NCT05210387 - Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections N/A
Completed NCT02573064 - Impact of Treatment With Colistin on Mortality Bacteremia Multiresistant Acinetobacter Baumannii Sensitive Colistin in Patients Critical N/A
Recruiting NCT05586815 - Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection Phase 4
Completed NCT00524290 - Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol
Completed NCT00462579 - Risk Factors for Carbapenem-resistant Acinetobacter Baumannii